200 related articles for article (PubMed ID: 6774915)
1. Prognostic factors and survival in multiple myeloma. Analysis of 91 cases treated by melphalan and prednisone.
Gobbi M; Cavo M; Savelli G; Baccarani M; Tura S
Haematologica; 1980 Aug; 65(4):437-45. PubMed ID: 6774915
[No Abstract] [Full Text] [Related]
2. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
3. [Prognosis in myelomatosis treated with prednisone and cytostatics].
Hansen OP; Jessen B; Videbaek A
Ugeskr Laeger; 1973 Jun; 135(23):1169-73. PubMed ID: 4757116
[No Abstract] [Full Text] [Related]
4. [Therapy results and clinical course in 91 cases of multiple myeloma with regard to their clinical staging (author's transl)].
Rubio Felix D; Giraldo MP; Raichs A; García Zueco JC; Mur P; Faura MV; Ruíz-Marcuello E; Piñan MA
Sangre (Barc); 1980; 25(1):25-34. PubMed ID: 7384962
[No Abstract] [Full Text] [Related]
5. [Survival and therapy of multiple myeloma. Apropos of 56 observed cases].
Locatelli F; Giovanelli E; Neretto G; Furno F; Pellerito R
Minerva Med; 1979 Mar; 70(13):925-33. PubMed ID: 220567
[TBL] [Abstract][Full Text] [Related]
6. [Multiple myeloma in stage I. Evaluation of the initial therapy].
Zapatero A; Blanco L; Sevilla F; Escribano L; Odriozola J; Montalbán C
Rev Clin Esp; 1985 May; 176(8):388-91. PubMed ID: 4023320
[No Abstract] [Full Text] [Related]
7. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
8. [Intermittent low dose melphalan and prednisone in multiple myeloma].
Yalon M; Levo Y; Many A; Ramot B
Harefuah; 1977 Apr; 92(7):296-8. PubMed ID: 863310
[No Abstract] [Full Text] [Related]
9. Prognostic factors for multiple myeloma in the dog.
Matus RE; Leifer CE; MacEwen EG; Hurvitz AI
J Am Vet Med Assoc; 1986 Jun; 188(11):1288-92. PubMed ID: 3721983
[TBL] [Abstract][Full Text] [Related]
10. Peptichemio in multiple myeloma. (Preliminary results).
Cavo M; Gobbi M; Tura S
Haematologica; 1981 Apr; 66(2):208-15. PubMed ID: 6791997
[No Abstract] [Full Text] [Related]
11. [Dysmyelopoietic syndrome 7 years after melphalan treatment of multiple myeloma. Clinical case].
Scolozzi R; Boccafogli A
Minerva Med; 1983 Jul; 74(28-29):1783-5. PubMed ID: 6866310
[TBL] [Abstract][Full Text] [Related]
12. IgD multiple myeloma. A report of three cases.
Martini R; Santini S; Bottari G
Minerva Med; 1996 Mar; 87(3):109-12. PubMed ID: 8668286
[TBL] [Abstract][Full Text] [Related]
13. [Multiple myeloma transforming into acute leukaemia (author's transl)].
Mayans J; Redon J; Badia L; Herranz C; Calabuig JR; Sanz MA; Soler A; Caballero M; Marty ML
Sangre (Barc); 1977; 22(6):1026-9. PubMed ID: 601670
[No Abstract] [Full Text] [Related]
14. [Recent progress in chemotherapy of multiple myeloma].
Tortarolo M; Cantore N; Russolillo S; Castaldo C; Buonanno G
Recenti Prog Med; 1978 Jul; 65(1):44-68. PubMed ID: 370935
[No Abstract] [Full Text] [Related]
15. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
[TBL] [Abstract][Full Text] [Related]
16. [Reclassification of multiple myeloma and calculation of the myelomatous mass as prognostic and therapeutic indications].
Ricci C; Coscia GC; Uberti M; Discalzi G; Racca P
Recenti Prog Med; 1982 Apr; 72(4):482-99. PubMed ID: 7146598
[No Abstract] [Full Text] [Related]
17. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
18. [Therapy of plasmacytoma].
Gassel WD; Sodomann CP
Ther Ggw; 1980 Sep; 119(9):980-1005. PubMed ID: 7466705
[No Abstract] [Full Text] [Related]
19. Peripheral neuropathy in osteosclerotic myeloma: clinical and electrodiagnostic improvement with chemotherapy.
Donofrio PD; Albers JW; Greenberg HS; Mitchell BS
Muscle Nerve; 1984 Feb; 7(2):137-41. PubMed ID: 6325905
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
Cavagnaro F; Lein JM; Pavlovsky S; Becherini JO; Pileggi JE; Micheo EQ; Jait C; Musso A; Suárez A; Pizzolato M
Cancer Treat Rep; 1980 Jan; 64(1):73-9. PubMed ID: 6991106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
